For millions of Americans, the prescription drug delivery system works: people, for the most part, can access the medications they need when they need them, and at the cost they expect and can afford. But “millions of Americans” does not
In case you missed it, a new article in Inside Health Policy reported that “Investors for eight major drug companies will vote throughout the spring on 11 proposals aimed at reducing the use of common drug patent practices and pharmaceutical lobbying activities
Study Finds Yearly Cost of Patent Thickets on Five Top-Selling Brand Name Drugs Ranges from $1.8 to $7.6 Billion.
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on the recent announcement from the Centers for Medicare and Medicaid Services (CMS) to allow Medicare Part D plans to substitute all FDA-approved biosimilars on their formularies.
Blumenthal-Cornyn Legislation Would Encourage More Generic and Biosimilar Competition in the Prescription Drug Market to Help Lower Costs for Patients (Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement today following the reintroduction of the “Affordable
Pharmacy benefit companies negotiate rebates from drug companies, which they pass to health plan sponsors. Health plan sponsors then use the rebates to make pharmacy benefits more affordable for patients.
PCMA Policy Platform Prioritizes Patients with Solutions to Promote Competition, Lower Drug Costs, Support Better Health Outcomes & Maximize the Value of Pharmacy Benefits (Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released today a new policy platform, “Unlocking
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today issued 21 policy solutions supported by America’s pharmacy benefit managers (PBMs) aimed at reducing prescription drug costs for patients and health plan sponsors. PBMs administer prescription drug plans for more than 266 million Americans with
With the recent launch of a new adalimumab biosimilar, the U.S. biosimilar market is becoming more competitive, increasing the potential for these more affordable options to play a critical role in helping to lower prescription drug costs for Americans. As biosimilar competition
©2024 PCMA. All Rights Reserved.
